Ambrisentan is a high affinity, propanoic acid-class, ETA-selective endothelin receptor antagonist (ERA) with once-daily oral doses. Ambrisentan doses of 2.5 and 5 mg once-daily improved 6-minute walk distance (6MWD) and delayed clinical worsening in a placebo-controlled PAH study (ARIES-2), with no incidence of serum aminotransferases >3xULN. ARIES-1 evaluated ambrisentan doses of 5 and 10 mg once-daily, compared to placebo
ARIES-1: A placebo-controlled, efficacy and safety study of ambrisentan in patients with pulmonary arterial hypertension / Oudiz RJ; Torres F; Frost AE; Badesch DB; Olchewski H; Galie N ; McGoon MD; McLaughlin V ; Rubin LJ.. - In: CHEST. - ISSN 0012-3692. - STAMPA. - 130:4 Supplement S(2006), pp. 121S-121S. (Intervento presentato al convegno Chest 2006 72nd Annual International Scientific Assembly of the American College of Chest Physicians tenutosi a Salt Lake City nel 21-26 October) [10.1378/chest.130.4_MeetingAbstracts.121S-a].
ARIES-1: A placebo-controlled, efficacy and safety study of ambrisentan in patients with pulmonary arterial hypertension
GALIE', NAZZARENO;
2006
Abstract
Ambrisentan is a high affinity, propanoic acid-class, ETA-selective endothelin receptor antagonist (ERA) with once-daily oral doses. Ambrisentan doses of 2.5 and 5 mg once-daily improved 6-minute walk distance (6MWD) and delayed clinical worsening in a placebo-controlled PAH study (ARIES-2), with no incidence of serum aminotransferases >3xULN. ARIES-1 evaluated ambrisentan doses of 5 and 10 mg once-daily, compared to placeboI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
